Mitochondrial oxidative stress: a target for treatment of doxorubicin-associated vascular endothelial dysfunction
Description: PROJECT NARRATIVE In the proposed project, I will investigate the mechanisms by which the highly effective anti-cancer, anthracycline-chemotherapy drug, doxorubicin (DOXO), mediates vascular endothelial dysfunction in preclinical mouse models, and whether these impairments occur through excess mitochondrial oxidative stress and an impaired compensatory increase in mitochondrial antioxidant defenses. Furthermore, I will determine whether the mitochondria-targeted antioxidant, Mitoquinol Mesylate (MitoQ®), can partially or fully restore initial impairments in vascular endothelial function or during middle-age in mice treated with DOXO during adolescence. Overall, this research will be the first to investigate the mechanisms by which DOXO induces endothelial dysfunction with the aim of identifying potential therapeutic targets for counteracting DOXO’s toxic effects on artery health, while also providing initial insight into a promising, novel treatment (MitoQ® therapy), thereby reducing risk of cardiovascular diseases.
Funding type: fellowship
Funder scheme: F32
Start date: 2020-03-09
End date: 2021-07-08
Investigator: ZACHARY S. CLAYTON (lead)
Institution: UNIVERSITY OF COLORADO
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Funded outputs count: 28
Funder award ID: F32HL151022
OpenAlex ID: G6190312808
